AstraZeneca scraps another GLP 1 candidate against type 2 diabetes retatrutide clinical trial saudi arabia Clinical trial results for retatrutide, Eli Lilly's next weight loss drug, A small study published in JAMA Ophthalmology analyzed data from nine patients who developed severe vision issues, including sudden blindness, while taking semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound). Whilst correlation is Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety Psychopharmacology Institute Whether you've seen the buzz online or you're just curious about the science, understanding GLP 1 is the first step toward a healthier you. GLP 1 does much more than support weight loss; they Novo Nordisk announces that CVS Caremark, the country's largest PBM, has decided Wegovy will be the preferred GLP 1 medicine covered for obesity on its template formularies